MGMT and glioblastoma: Although classification has been established on the basis of IDH status among GBM, some studies indicated that IDH mutation, MGMT promoter methylation status, 1p/19q loss independently associated with favorable outcome in temozolomide (TMZ) + radiotherapy-treated GBM patients.